Last reviewed · How we verify
olanzapine + fluoxetine
Olanzapine blocks dopamine and serotonin receptors while fluoxetine inhibits serotonin reuptake, together providing antipsychotic and antidepressant effects.
Olanzapine blocks dopamine and serotonin receptors while fluoxetine inhibits serotonin reuptake, together providing antipsychotic and antidepressant effects. Used for Bipolar I disorder depression, Treatment-resistant depression with psychotic features.
At a glance
| Generic name | olanzapine + fluoxetine |
|---|---|
| Sponsor | University of Florida |
| Drug class | Atypical antipsychotic + SSRI combination |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, reducing psychotic symptoms. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake. The combination targets both dopaminergic and serotonergic pathways to address psychotic and depressive symptoms simultaneously.
Approved indications
- Bipolar I disorder depression
- Treatment-resistant depression with psychotic features
Common side effects
- Weight gain
- Sedation
- Nausea
- Akathisia
- Metabolic syndrome
Key clinical trials
- Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (PHASE1, PHASE2)
- National Pregnancy Registry for Psychiatric Medications
- Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression (PHASE4)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression (PHASE3)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- olanzapine + fluoxetine CI brief — competitive landscape report
- olanzapine + fluoxetine updates RSS · CI watch RSS
- University of Florida portfolio CI